BON Announces Apple Polyphenol Commercial Order Signed
XI'AN, China, April 11, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking 24-month supply agreement worth $12M with Shanghai Yunsheng, China's premier functional ingredients distributor, to co-develop next-generation apple polyphenol-infused health solutions. The partnership leverages BON's patented extraction technology to deliver science-backed formulations combining antioxidant-rich apple polyphenols with plant-based proteins, proven to support weight management and metabolic health.
Protein supplements have evolved into a mainstream wellness staple over decades, cementing their role in fitness regimens, immune health protocols, and longevity-focused nutrition. The strategic incorporation of apple polyphenols into these formulations now unlocks targeted benefits-clinically validated lipid management, enhanced body composition outcomes, and mitigation of age-related muscle atrophy-positioning this innovation at the convergence of proven demand and novel functionality.
Early market validation proves compelling-comparable apple polyphenol blends have achieved blockbuster status since launch, selling over half a million units monthly and generating $40M in recurring revenue. Industry analysts note this reflects growing consumer willingness to pay premium pricing for validated "nutraceutical crossover" products.
'As one of the world's premier apple polyphenol suppliers, we're leveraging our vertically integrated supply chain to dominate this high-growth niche,' said Yongwei Hu, Chairman and CEO of the Company, 'the company anticipates compounding revenue streams from the ingredient's dual applications-both as a standalone nutraceutical and as a functional food additive-while maintaining disciplined margin control to maximize shareholder returns.'
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
12 minutes ago
- Miami Herald
Famous fast-food chain unveils bold new menu to win back customers
Expanding its menu from basic dishes to chef-curated creations may seem like an unexpected choice for a fast-casual restaurant. However, when aiming to attract a bigger audience, range is key if a chain needs to appeal to more taste buds. Don't miss the move: Subscribe to TheStreet's free daily newsletter A slowdown in consumer spending and inflation have started to affect even the most popular restaurant chains, causing many to close locations due to underperformance and sales declines. Related: McDonald's brings back unexpected breakfast item after 6 years Companies tend to make this move as a last resort to mitigate financial strain and reduce costs, so no more unnecessary debt accumulates. However, one restaurant chain made a strategic move that has worked in its favor, as it has managed to turn around its declining numbers. Image source: Shutterstock Noodles & Company has partnered with Food Network to release four new noodle-based dishes, renowned as the network's favorites. These new entrées were hand-picked by Food Network and include Basil Pesto Cavatappi, Buffalo Chicken Ranch Mac & Cheese, Rigatoni Rosa with Parmesan Chicken, and Lemon Garlic Shrimp Scampi. More Food News: Popular chicken chain menu brings back fan-favorite value combosPopular chicken chain launches its version of McDonald's wrapsPopular fast-food burger chain aims major comeback amid closures "We're excited to introduce guests to a lineup of reimagined favorites and bold new flavors that showcase our culinary expertise," said Noodles & Company SVP of Marketing Stephen Kennedy in a press release. "It's an honor to have four of our most popular noodle bowls selected by the experts at Food Network as 'Food Network Favorites.' These dishes promise to deliver comfort, indulgence, and creativity in every bowl - just as we always strive to do," he added. To strengthen its business, Noodles & Company (NDLS) initiated a menu revamp in March, adding new dishes and improving fan favorites to better meet consumer demands and attract new audiences. Related: Popular fast-food burger chain to open first store in new market This menu transformation resonated well with consumers, driving an increase in sales during the first quarter of 2025. Total revenues were up 2% compared to the prior year, and same-store sales increased 4.4% system-wide. However, in May 2025, Noodles & Company shared plans to close some of its more than 450 restaurants, including approximately 13 to 17 company-owned and four franchise locations in 2025. The chain attributed these closures to higher food costs and increased marketing expenses. This new round of menu improvements in partnership with Food Network might be just what Noodles & Company needs to prevent further restaurant closures. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
32 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why Palantir Technologies Hit a New All-Time High on Wednesday
One Wall Street analyst boosted Palantir's price target, despite maintaining a sell rating. The reasoning for the move was decidedly bullish. The key factor in the rating is Palantir's frothy valuation. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock continued its epic run on Wednesday, climbing as much as 5.4%. As of 3:37 p.m. ET, the stock was still up 3%. The artificial intelligence (AI) software and data mining specialist has climbed to new heights several times in recent weeks, with its stock notching a new all-time high on Wednesday. That puts the stock up more than 80% so far this year. The catalyst behind today's move was a reluctant nod from a Wall Street analyst. Mizuho analyst Matthew Broome kept an underperform (sell) rating on Palantir stock, but raised his price target for Palantir to $116, up from its previous level of $94. For those keeping score at home, that's roughly 12% below the stock's closing price on Tuesday, so the analyst is obviously playing catch-up. Broome cited Palantir's "strong recent execution and significant upward revisions" for his price target increase. The analyst also noted the company's "strong strategic positioning with large customers and potential for further accelerated growth in future years." So, if the analyst is so bullish on Palantir, why maintain the sell rating? In a word: valuation. Palantir stock is currently selling for 594 times earnings and 109 times sales. With multiples of that magnitude, it isn't for the faint of heart. Even factoring in the company's accelerating growth, it sports a price-to-earnings growth (PEG) ratio of 6, when any number higher than 1 is overvalued. Don't get me wrong: I'm a dyed-in-the-wool Palantir bull. However, valuation is a fickle mistress, and any failure by the company to execute -- real or perceived -- could bring the stock crashing down. In fact, I wouldn't be surprised to see Palantir stock get cut in half at some point over the next year -- before climbing to even greater heights. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Danny Vena has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Why Palantir Technologies Hit a New All-Time High on Wednesday was originally published by The Motley Fool
